LOX and prostate carcinoma: In this study we observed that the inherited genetic variants in LOX and KDR seem to modulate the expression of LOX and VEGFR2 in carcinoma cells, supporting a gene-tumor microenvironment interaction in the activation of hypoxia-driven pathways in prostate carcinoma.